argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
11 mrt 2015 - 07:23
Statutaire naam
argenx SE
Titel
arGEN-X to Host Conference Call & Webcast to Report Fourth Quarter Business Update and Full Year 2014 Financial Results on March 18, 2015
Bericht
Breda, the Netherlands / Ghent, Belgium, 11 March 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced it will report its fourth quarter business update and its full year 2014 financial results after market close on Wednesday, 18 March 2015.
The arGEN-X management team will host a conference call and audio webcast at 6:00pm CET (midday ET) to discuss the financial results, as well as provide a fourth quarter business update.
To participate in the conference call, please select your phone number here, and use the confirmation code 92395735. The webcast may be accessed on the homepage of the arGEN-X website at www.argen-x.com or by clicking here.
A replay of the webcast will also be available at the arGEN-X website: www.argen-x.com/reports-and-presentations/
Gerelateerde downloads
Datum laatste update: 18 december 2025